By biomarkers I mean all the broad range of blood test measures like ApoB, etc. I don’t put any value today in the methylation clocks or other aging clocks given the state of the science.
I am simply saying that as long as all the significant blood measures of health and disease risk are in very positive ranges, and I feel good, then it seems like the risk of continuing rapamycin is manageable.
There could always be some effect that isn’t shown in our typical battery of blood tests and functional measures (blood pressure, etc), and that is also deleterious, so I try to be open to new testing, etc
Regarding mouse studies that don’t translate to humans, see this thread Most mouse research doesn't translate to humans - why do we think rapamycin is different? - #4 by RapAdmin
And if course the drug trials that fail after an animal study are usually only tested in a single species (typically mice), but rapamycin has been tested in 5 or 6 model organisms from nematodes to monkeys and successfully extended lifespan in every one. How many drugs have been tested in this many model organisms, and already been FDA approved , and then failed in a new indication? It could happen… But the odds seem to be it will continue working.